MarketCap
Facebook
X
Telegram
Pro-Dex Net Income | PDEX
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Pro-Dex
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.7 M | 8.98 M | 2.13 M | 7.07 M | 2.75 M | 1.08 M | 1.79 M | 4.15 M | 1.62 M | 5.08 M | 822 K | -365 K | -488 K | -1.78 M | -876 K | 2.64 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.7 M | -1.78 M | 3.02 M |
Quarterly Net Income Pro-Dex
| 2026-Q4 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 3.94 M | 2.19 M | 4.68 M | 2.19 M | 3.28 M | 2.04 M | 3.28 M | 2.04 M | 2.47 M | - | 655 K | 500 K | -615 K | - | 1.62 M | 2.75 M | 1.2 M | 1.96 M | 462 K | 925 K | 1.06 M | 1.99 M | 2.13 M | 1.75 M | 1.16 M | 337 K | 1.26 M | 1.25 M | 1.1 M | 1.25 M | 1.1 M | 1.18 M | 1.35 M | 1.18 M | 1.35 M | 345 K | 628 K | 345 K | 628 K | 3.19 M | 286 K | 3.19 M | 286 K | 391 K | -125 K | 391 K | -125 K | -192 K | -170 K | -192 K | -170 K | -338 K | 212 K | -338 K | 212 K | -348 K | -17 K | -348 K | -17 K | -292 K | 446 K | -292 K | 446 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.68 M | -615 K | 1.03 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical instruments industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
STAAR Surgical Company
STAA
|
-80.4 M | $ 24.16 | 2.94 % | $ 1.2 B |  USA |
 |
Stereotaxis
STXS
|
-21.6 M | $ 1.3 | 0.36 % | $ 118 M | USA |
 |
Microbot Medical
MBOT
|
-13.1 M | $ 1.5 | 4.17 % | $ 68.7 M |  Israel |
 |
Retractable Technologies
RVP
|
-12.6 M | $ 0.7 | 1.29 % | $ 21 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
-598 M | $ 10.99 | 0.48 % | $ 2.19 B | USA |
 |
Atrion Corporation
ATRI
|
19.4 M | - | - | $ 810 M | USA |
 |
Utah Medical Products
UTMD
|
2.56 M | $ 69.16 | 0.55 % | $ 224 M | USA |
 |
Teleflex Incorporated
TFX
|
-906 M | $ 137.0 | 0.38 % | $ 6.11 B | USA |
 |
West Pharmaceutical Services
WST
|
494 M | $ 337.75 | 0.03 % | $ 24.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
-24.5 M | - | - | $ 282 M | USA |
 |
Alcon
ALC
|
980 M | $ 69.12 | 0.3 % | $ 34.1 B |  Schweiz |
 |
Cantel Medical Corp.
CMD
|
13.7 M | - | -1.18 % | $ 3.4 B | USA |
 |
AngioDynamics
ANGO
|
-36.7 M | $ 15.22 | 0.13 % | $ 632 M | USA |
 |
AtriCure
ATRC
|
-11.4 M | $ 53.73 | 4.29 % | $ 2.57 B | USA |
 |
Baxter International
BAX
|
-957 M | $ 24.86 | 1.02 % | $ 12.8 B | USA |
 |
Becton, Dickinson and Company
BDX
|
1.68 B | $ 179.1 | 0.05 % | $ 51.5 B | USA |
 |
BioLife Solutions
BLFS
|
-4.6 M | $ 35.38 | 0.37 % | $ 1.69 B | USA |
 |
Luminex Corporation
LMNX
|
15.2 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
-17.6 M | - | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
56.2 M | - | - | $ 955 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
223 M | - | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
292 M | - | -0.02 % | $ 16.3 B | USA |
 |
The Cooper Companies
COO
|
375 M | $ 67.69 | 1.31 % | $ 13.5 B | USA |
 |
electroCore
ECOR
|
-14 M | $ 9.08 | 1.1 % | $ 77 K | USA |
 |
Glaukos Corporation
GKOS
|
-188 M | $ 185.04 | 4.27 % | $ 10.6 B | USA |
 |
NeuroMetrix
NURO
|
-7.81 M | - | 5.05 % | $ 9.02 M | USA |
 |
Haemonetics Corporation
HAE
|
97.3 M | $ 102.84 | 0.24 % | $ 4.85 B | USA |
 |
Harvard Bioscience
HBIO
|
-56.7 M | $ 7.95 | 1.62 % | $ 353 M | USA |
 |
ICU Medical
ICUI
|
732 K | $ 160.89 | 0.78 % | $ 3.96 B | USA |
 |
InfuSystem Holdings
INFU
|
6.63 M | $ 11.89 | 0.74 % | $ 246 M | USA |
 |
iRhythm Technologies
IRTC
|
-45 M | $ 122.24 | 0.77 % | $ 3.91 B | USA |
 |
Intuitive Surgical
ISRG
|
2.86 B | $ 350.16 | 0.28 % | $ 125 B | USA |
 |
Repro Med Systems
KRMD
|
-2.64 M | $ 3.17 | 0.93 % | $ 146 M | USA |
 |
LeMaitre Vascular
LMAT
|
57.7 M | $ 79.59 | 0.22 % | $ 1.8 B | USA |
 |
Milestone Scientific
MLSS
|
-5.72 M | $ 0.44 | 0.52 % | $ 36.1 M | USA |
 |
Merit Medical Systems
MMSI
|
128 M | $ 87.38 | 1.16 % | $ 5.17 B | USA |
 |
Nephros
NEPH
|
1.19 M | $ 4.36 | 7.39 % | $ 46.3 M | USA |
 |
Envista Holdings Corporation
NVST
|
47 M | $ 26.81 | 0.73 % | $ 4.5 B | USA |
 |
OraSure Technologies
OSUR
|
-68.7 M | $ 3.39 | 2.27 % | $ 249 M | USA |
 |
Pulse Biosciences
PLSE
|
-72.8 M | $ 48.79 | 3.85 % | $ 3.29 B | USA |
 |
ResMed
RMD
|
1.52 B | $ 221.05 | 0.04 % | $ 32.2 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
-50.3 M | - | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
-103 M | - | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
-305 M | - | - | $ 9.59 B | USA |
 |
Predictive Oncology
POAI
|
-233 M | - | - | $ 31.1 M | USA |
 |
Repligen Corporation
RGEN
|
48.9 M | $ 168.53 | 0.55 % | $ 9.48 M | USA |
 |
STERIS plc
STE
|
782 M | $ 218.44 | 0.31 % | $ 21.5 B | USA |